Articles On Invion (ASX:IVX)

ASX 200 closes about 0.06% in the green (so, really, we ended in the chartreuse) down -1.2 in August Telco and IT Sectors offset Staples and Energy losses Small cap winners include 29M, CDX and HLA   Volatility, uncertainty and indecisio...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX 200 benchmark rises almost 0.6% Tech Sector recovers Wednesday’s losses, after Nasdaq positivity  Miners lead small cap gains, ERW, RDN, AZS winning at home in Andover South   The Australian share market was up and about early on Thur...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in...

ASX benchmark finishes the flat, after struggling to find traction since mid-morning Health Care romped home to win Best Sector today, up more than 0.4% Errawarra’s nearology has continued to pay off, adding around 50% more today.   Whil...

ASX sleepwalks to an underwhelming -0.3% loss for the day.  Real Estate the ‘highlight’, on a paltry +0.5% Lithium Australia’s tech-for-facilities deal with MinRes saw it climb past +80% for the session.   It’s been a weak and sorry day o...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 finishes up 1.56%  The ASX XEC rises 1.52% All 11 sectors were higher lead by Real Estate   The ASX 200 managed a decent 1.56% lift today, and the ASX XEC was also in the green, up 1.52%.  All of 11 sectors were higher, led b...

S&P/ASX 200 closes well in the red today: -1.24% after US stocks dipped on the back of Fed hawkishness  Sectors-wise, IT was the only group finishing vaguely in the green, with Materials Discretionary and Financials stocks largely hamm...

S&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or something Sectors-wise, Telcos are ringing in the gainz… annnd that’s about it. Okay, Utilities are going alright  Standout stocks: Krakatoa...

The S&P ASX 200 was up 1.76% in June, with large caps performing the best and small caps lagging blue chips The S&P/ASX 200 Materials was the best performing sector in June, up 4.8% coming back from April drop An ASX favourite lith...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

ASX has finished 0.5% ahead, despite Wall Street’s flabby performance on Friday. Health Care has taken a positive 1.8% step towards fixing last week’s -6.1% disaster. Gold 50 has topped the charts after hitting stellar intercepts at its Ar...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

S&P/ASX 200 closes up 0.40%, while the emerging companies index rises 0.43% Algerian mining regulator issues a mining permit for Terramin’s Tala Hamza zinc-lead project Retail component of Next DC’s entitlement offer opens and is expec...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed up a 1.09% lift while Financials weighed heavily on -0.71% Magnum Mining wins the Small Caps trophy with +44.1% thanks to Mitsubishi deal...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX climbed as high as +1.3%, easing slightly to close up 0.9%. XEC Emerging Companies and Goldies duke it out to see who can close flattest. Investors are set to pocket $35 billion in dividends between now and EOFY.   Do Not Adjust Your...

Highlights Invion has released its H1FY23 report, highlighting progress with respect to its Photosoft™ technology and lead drug candidate INV043. Photosoft™ has demonstrated positive results against antibiotic resistant MRSA bacteria,...

Highlights In a recent report and accompanying blog, CSIRO has talked about the threat that superbugs pose to humans Antimicrobial resistance is being fuelled by factors like climate change, which let superbugs to thrive in warm temper...

Highlights Photodynamic therapy (PDT) is designed to treat cancer patients using drugs activated by light. Invion Limited (ASX:IVX) is undertaking R&D of next-gen PDT as a treatment for cancer and infectious diseases. Invion’s lea...

INOVIQ announced positive results on SUBB2M Invion expands to international markets INOVIQ (ASX:IIQ) rose 5% this morning after announcing positive results for its SUBB2M breast cancer test. The company said its SubB2M-CA15.3 breast cance...

Highlights Invion and RMW Cho Group have executed a conditional agreement for the expansion of existing arrangements to co-develop Photosoft™ technology relating infectious diseases (ID indications). As per the agreement, Invion will g...

The ASX is set to rise today after a seesaw session on Wall Street Fed Chairman Jerome Powell spoke to David Rubenstein Medibank Private was hit by a class action lawsuit The ASX is set to open higher after some wild swings in New York. A...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Highlights Invion has tabled its December 2022 quarter, highlighting promising research outcomes with PhotosoftTM technology against infectious diseases. In vitro study outcomes indicated PhotosoftTM compounds’ activity against multipl...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Highlights Invion witnessed successful research outcomes in 2022, laying the groundwork for an exciting 2023 The combination therapy of the company’s lead candidate INV043 with ICI therapy resulted in a nearly 65% reduction in tumour s...

Highlights The world needs to focus on developing innovative treatments to be prepared for the next pandemic Invion’s research on PhotosoftTM compounds has demonstrated effectiveness against dengue, the Zika virus and COVID-19 variants...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Highlights Invion is going strong with research work focused on cancer and infectious diseases. The lead drug candidate INV043 has demonstrated promising results in studies covering triple negative breast cancer and anal cancers. INV0...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Highlights Invion reports that the results of its latest study indicate promise for the PhotosoftTM technology across COVID-19 variants. In the study, 9 of the 10 PhotosoftTM compounds tested displayed antiviral activity against both D...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Benchmark set to end the day down 1.5% Small caps smashed down 4.2% Greenwing up 70% on Chinese investment   Look. No-one likes Monday’s except possibly the last four or five Prime Ministers. I definitely sense S Morrison and K Rudd and c...

Highlights Invion is riding high on latest study outcomes indicating the effectiveness of its lead drug candidate INV043 in a clinically important class of tumour. In an in vitro set up, INV043 proved effective against cell lines relat...

Invion’s lead drug is found to be effective against anal cancer Althea launches new cannabis products Invion (ASX:IVX) surged 17% this morning after telling the market that its lead drug INV043 is effective against anal cancer. A vitro st...

Invion (IVX) claims the first set of results from in-vitro lab tests of its INV043 product confirm the drug’s potential to treat the full range of anal cancersThe tests, completed at the Peter MacCallum Cancer Centre in Melbourne, show the...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Highlights Invion has secured positive screening results from the in vitro study of PhotosoftTM technology against the Zika virus. Currently, there is no treatment available for the Zika virus, and its market is estimated to be worth $...